Virtual Library
Start Your Search
O.J. Kwon
Author of
-
+
P1.21 - Poster Session 1 - Diagnosis and Staging (ID 169)
- Event: WCLC 2013
- Type: Poster Session
- Track: Prevention & Epidemiology
- Presentations: 1
- Moderators:
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.21-009 - Reliability of transthoracic fine needle aspiration and core needle biopsy for the diagnosis of pulmonary mucinous adenocarcinoma (ID 2759)
09:30 - 09:30 | Author(s): O.J. Kwon
- Abstract
Background
In case of mucinous adenocarcinoma (MA), cytologic atypia is usually mild to moderate and can be absent in some cases, creating a diagnostic pitfall in recognizing MA in small tissue biopsy and cytology specimens. Specific diagnosis of mucinous subtype in small tissue n FNA is important because it is considered an invasive neoplasm until proven otherwise, and it carries a worse prognosis for its aggressive behavior with frequent multicentricity and intrapulmonary metastatic spread. The purpose of this study was to evaluate the diagnostic accuracy of transthoracic fine needle aspiration (FNA) or core needle biopsy (CNB) of MA of the lung.Methods
We retrospectively reviewed a consecutive series of 184 patients who underwent curative operation for MA. Among those patients, 105 patients underwent pre-operative percutaneous FNA (n= 34) or CNB (n= 79). Eight patients underwent both FNA and CNB for the same tumors. Diagnostic accuracies of FNA and CNB for MA were evaluated, and the contribution of various clinicopathologic parameters to subtyping accuracy was analyzed.Results
Diagnostic accuracies of FNA and CNB in determining malignancy were 67.6% and 87.3%, respectively. 20.6% and 59.5% were successfully diagnosed as MA through FNA and CNB, respectively. Univariate analysis implicated type of procedure and prominent growth pattern of mucinous adenocarcinoma as significant factors for successful pathologic diagnosis. Figure 1Conclusion
CNB of diagnosis of MA is feasible and accurate. Our data support the suitability of small biopsy specimens for the new therapeutic paradigms even in mucinous adenocarcinoma.
-
+
P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)
- Event: WCLC 2013
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 1
- Moderators:
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.12-017 - Clinical Impact of Dynamic Contrast-Enhanced CT in Stage IA Non-Small Cell Lung Cancer: Net Enhancement is an Independent Predictor of Recurrence. (ID 2501)
09:30 - 09:30 | Author(s): O.J. Kwon
- Abstract
Background
Microvessel density is known as a prognostic indicator for patients with solid organ malignancy and the extent of enhancement on CT is positively correlated with the extent of microvessel density. The purpose of this study is to investigate the prognostic significance of dynamic contrast-enhanced (DCE) CT in patients with stage IA non-small cell lung cancer (NSCLC).Methods
From January 2003 through December 2006, we retrospectively enrolled 118 patients (men: women = 67:51; mean age, 58.6 years) with stage IA NSCLC who underwent DCE CT with helical technique (unenhanced images and series of dynamic enhanced images covering primary lung cancer at 30, 60, 90 and 120 seconds and 5 and 10 minutes) after intravenous contrast medium injection and followed by curative surgery. Data were collected on age, pathologic subtype, and size, peak attenuation and net enhancement of primary lung cancer and then correlated with overall, metastasis-free, and recurrence-free survivals that occurred through December 31, 2011.Results
Figure 1In multivariate analysis, net enhancement of primary lung cancer was independently associated with recurrence (hazard ratio [HR] 1.024, P=.013), metastasis (HR 1.027, P=.023), and overall survival (HR 1.025, P=.044). Net enhancement of 80 HU predicted significantly higher risk for the recurrence (P=.028) and metastasis (P=.025) after curative surgery of stage IA lung cancer. The significance of tumor size was proved only in the correlation with recurrence (HR 1.069, P=.038) .Conclusion
Our study confirmed the prognostic significance of net enhancement as an indirect biomarker of tumor angiogenesis for patients with stage IA NSCLC.